Meridian Bioscience expands with purchase of Vybion assets

Meridian Bioscience is expanding its already growing life science business with the purchase of a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc., an Ithaca, N.Y.-based biotech company.  Cincinnati-based Meridian says the deal will add manufacturing know-how and access to patents to develop and produce recombinant proteins, an emerging technology used in a wide variety of medical and scientific applications. Meridian owns a portfolio of highly specialized biologicals that it manufactures and distributes to hospitals, physicians, pharmaceutical companies and researchers. It manufactures tools to diagnose infectious diseases and monitor human protein levels in hepatitis, HIV, and cardiac disease patients. The Vybion purchase "relates to Meridian's goals of growing its life science business through internal growth and acquisitions," sayd Richard Eberly, president of its Meridian Life Science unit.

Writer: David Holthaus
Source: John Kraeutler, Meridian Bioscience